赛诺菲新一代长效胰岛素的在华专利分析  

Research of Patents Applicated by Sanofi on the Topic of New long Acting Insulin Product in China

作　　者：潘晓娇[1] 孙尚瑜[1] 

机构地区：[1]国家知识产权局专利局专利审查协作江苏中心,江苏苏州215163

出　　处：《广东化工》2016年第15期138-138,153,共2页Guangdong Chemical Industry

摘　　要：赛诺菲近期推出新一代长效胰岛素产品——Toujeo,即300 U/m L甘精胰岛素制剂。文章对赛诺菲公司就Toujeo相关技术在中国的专利申请进行了研究,重点分析了这些专利申请的技术特点和审查情况,以期为国内制药企业和研发单位提供参考。Sanofi recently provided new long acting insulin product Toujeo, the preparation comprising 300 U/mL glargine insulin. The article researched the patent applications from Sanofi on the topic of Toujeo related technology, focused on technique characters and examinations of the patent applications, to provide information for related drug companies and research centers.

关 键 词：赛诺菲 甘精胰岛素 Toujeo 专利 

分 类 号：TQ[化学工程]